Clinical Trial: Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213583) titled 'Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM' on Sept. 15.

Brief Summary: This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.

Study Start Date: Aug. 28

Study Type: INTERVENTIONAL

Condition: Amyloid Transthyretin Cardiomyopathy

Intervention: DRUG: ALXN2220

Participants will receive ALXN2220 via IV infusion.

Recruitment Status: RECRUITING

Sponsor: Neurimmune AG

Disclaimer: Curated by HT Syndication....